Format

Send to

Choose Destination
Clin Transl Oncol. 2016 Nov;18(11):1062-1071. Epub 2016 Mar 10.

Survival in glioblastoma: a review on the impact of treatment modalities.

Author information

1
Servicio de Neurocirugía, Hospital Universitario de Burgos, Avda Islas Baleares 3, 09006, Burgos, Spain. pedrodl@yahoo.com.
2
Servicio de Oncología Radioterápica, Hospital Universitario de Burgos, Avda Islas Baleares 3, 09006, Burgos, Spain.

Abstract

Glioblastoma (GBM) is the most common and lethal tumor of the central nervous system. The natural history of treated GBM remains very poor with 5-year survival rates of 5 %. Survival has not significantly improved over the last decades. Currently, the best that can be offered is a modest 14-month overall median survival in patients undergoing maximum safe resection plus adjuvant chemoradiotherapy. Prognostic factors involved in survival include age, performance status, grade, specific markers (MGMT methylation, mutation of IDH1, IDH2 or TERT, 1p19q codeletion, overexpression of EGFR, etc.) and, likely, the extent of resection. Certain adjuncts to surgery, especially cortical mapping and 5-ALA fluorescence, favor higher rates of gross total resection with apparent positive impact on survival. Recurrent tumors can be offered re-intervention, participation in clinical trials, anti-angiogenic agent or local electric field therapy, without an evident impact on survival. Molecular-targeted therapies, immunotherapy and gene therapy are promising tools currently under research.

KEYWORDS:

Chemotherapy; Glioblastoma; Prognosis; Radiotherapy; Survival; Tumor marker

PMID:
26960561
DOI:
10.1007/s12094-016-1497-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center